FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics'), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET.
The event will feature presentations from the following members of the Company's management:
Pete O'Heeron, Chief Executive Officer
Hamid Khoja, PhD, Chief Scientific Officer
Robert Hoffman, Interim Chief Financial Officer
The event will highlight FibroBiologics' research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases.
A live Q&A session will follow the formal presentations. An audio recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event.
In addition, FibroBiologics will be presenting at the 2025 BIO CEO & Investor Conference in New York, NY, from February 10-11. Details of the event are as follows:
Date: Tuesday, February 11Time: 11:15 a.m. ETLocation: The New York Marriott MarquisTrack: Plymouth Room
To learn more about the event, please visit https://bcic.bio.org/, or to schedule one-on-one meetings, please email FibroBiologicsIR@russopr.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:info@fibrobiologics.com
Investor Relations:Nic Johnson Russo Partners(212) 845-4242fibrobiologicsIR@russopr.com
Media Contact:Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
21 minutes ago
- Wall Street Journal
Iran Says It Will Scale Up Nuclear Work After U.N. Atomic Agency Vote
Iran said it would open a new uranium enrichment facility and increase its production of highly enriched fissile material after the U.N. atomic agency member states declared Tehran had failed to comply with its nuclear nonproliferation obligations, casting a fresh shadow over struggling U.S.-Iran nuclear talks. Iran's announcement comes ahead of a sixth round of nuclear negotiations between the U.S. and Iran expected on Sunday. President Trump said on Monday he had grown less confident about striking a deal with Tehran.
Yahoo
28 minutes ago
- Yahoo
Australia's defense minister downplays concerns over Pentagon review of multi-billion submarine deal
BANGKOK (AP) — Australia's defense minister dismissed concerns Thursday that a deal between the U.S., Australia and Britain to provide his country with nuclear-powered submarines could be in jeopardy, following a report that the Pentagon had ordered a review. Australian Defense Minister Richard Marles told Sky News Australia that he had known about the review of the deal 'for some time," saying that it was a 'very natural step for the incoming administration to take.' He noted that the UK's government also reviewed the deal, the centerpiece of a three-way alliance known as AUKUS after it was elected, and that his own government had looked at it as part of its own review of Australia's entire defense posture. "I think an incoming government having a look at this is something that they have a perfect right to do and we welcome it and we'll work with it,' he said. The deal, worth more than $200 billion, was signed between the three countries in 2021 under then President Joe Biden, designed to provide Australia, one of Washington's staunchest allies in the region, with greater maritime capabilities to counter China's increasingly strong navy. The deal also involves the U.S. selling several of its Virginia-class submarines to Australia to bridge the gap as the new submarines are being jointly built. In January, Australia made the first of six $500 million payments to the U.S. under the AUKUS deal, meant to bolster American submarine manufacturing. Marles met with U.S. Defense Secretary Pete Hegseth on the sidelines of a defense conference in Singapore less than two weeks ago, and told reporters afterward that he had come away with 'a sense of confidence about the way in which AUKUS is proceeding.' 'AUKUS is on track and we are meeting all the timelines that are associated with it,' he said. 'We are very optimistic.' Hegseth's address to the defense forum made multiple mentions of cooperation with Australia but no reference to AUKUS, however, though he did later mention the deal when he was taking questions. Hegseth did urge allies in the Indo-Pacific to increase their defense spending, and underscored the need for a 'strong, resolute and capable network of allies and partners' as the U.S. seeks to counter China.
Forbes
35 minutes ago
- Forbes
When Will Intel Rebound?
CANADA - 2025/05/26: In this photo illustration, the Intel Corporation logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Intel (NASDAQ:INTC) stock jumped by nearly 8% during Tuesday's trading session. While there weren't many stock-specific factors to justify such a significant move, tech stocks overall have been on an upward trend, driven by positive sentiment regarding the generative artificial intelligence phenomenon. Additionally, U.S. and Chinese officials are currently engaged in trade discussions in London, reportedly touching on export restrictions for various products, including semiconductors and rare earth metals, which may have contributed to the rise in Intel stock. Furthermore, strong fund inflows into technology funds like the Invesco QQQ Trust during the month of May also reflect the favorable outlook for the sector. Intel's stock has faced pressure over the past year due to its substantial investments in the foundry sector and a loss of market share in the server and PC spaces to competitors like AMD. Our evaluation of Intel based on essential metrics of Growth, Profitability, Financial Stability, and Downturn Resilience indicates that the company is experiencing poor operating performance, as outlined below. Nevertheless, if you are looking for potential upside with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative that has surpassed the S&P 500, yielding returns of over 91% since its launch. Based on your expenditure per dollar of sales or profit, INTC stock appears inexpensive when contrasted with the broader market. • Intel possesses a price-to-sales (P/S) ratio of 1.7 versus a figure of 3.0 for the S&P 500 • Moreover, the company's price-to-free cash flow (P/FCF) ratio stands at 8.6 against 20.5 for S&P 500 Intel's Revenues have decreased in the past few years. • Intel has experienced a decline in its top line at an average rate of 11.2% over the last 3 years (in comparison to a growth of 5.5% for S&P 500) • Its revenues have dropped by 4.0% from $55 Bil to $53 Bil in the past 12 months (while S&P 500 grew by 5.5%) • Additionally, its quarterly revenues contracted by 0.4% to $13 Bil in the most recent quarter from $13 Bil a year ago (versus a 4.8% increase for S&P 500) Intel's profit margins are significantly worse than most companies in the Trefis coverage universe. • Intel's Operating Income for the last four quarters amounted to $-4.1 Bil, reflecting a very poor Operating Margin of -7.8% (in contrast to 13.2% for S&P 500) • Intel's Operating Cash Flow (OCF) during this period was $10 Bil, indicating a moderate OCF Margin of 19.5% (against 14.9% for S&P 500) • For the last four-quarter span, Intel's Net Income was $-19 Bil, signifying a very poor Net Income Margin of -36.2% (compared to 11.6% for S&P 500) Intel's balance sheet appears to be adequate. • Intel's debt stood at $50 Bil at the conclusion of the most recent quarter, while its market capitalization is $96 Bil (as of 6/10/2025). This indicates a poor Debt-to-Equity Ratio of 56.3% (compared to 19.9% for S&P 500). [Note: A low Debt-to-Equity Ratio is preferable] • Total assets for Intel amount to $192 Bil, with cash (inclusive of cash equivalents) comprising $21 Bil. This results in a strong Cash-to-Assets Ratio of 10.9% (in contrast to 13.8% for S&P 500) INTC stock has performed worse than the benchmark S&P 500 index during some recent downturns. Concerned about the effects of a market crash on INTC stock? Our dashboard How Low Can Intel Stock Go In A Market Crash? offers a thorough analysis of how the stock reacted during and after prior strong market downturns. • INTC stock experienced a 63.3% decline from a peak of $68.26 on April 9, 2021, to $25.04 on October 11, 2022, compared to a peak-to-trough drop of 25.4% for the S&P 500 • The stock has not yet returned to its pre-Crisis high • Since then, the highest point the stock has reached is 50.76 on December 27, 2023, and it currently trades at approximately $22 • INTC stock declined by 34.8% from a high of $68.47 on January 24, 2020, to $44.61 on March 16, 2020, versus a peak-to-trough decline of 33.9% for the S&P 500 • The stock has not yet returned to its pre-Crisis high • INTC stock saw a decrease of 56.8% from a high of $27.98 on December 6, 2007, to $12.08 on February 23, 2009, compared to a peak-to-trough decline of 56.8% for the S&P 500 • The stock fully recovered to its pre-Crisis peak by March 26, 2012 Currently, Intel's recent performance has been lackluster, exhibiting inadequate growth and profitability as well as low resilience in downturns. Nonetheless, looking forward, there is potential for improvement. Intel's foundry operations, previously a weak area, may experience a turnaround within the next two years with the introduction of its advanced 18A process node, already attracting clients such as Amazon and Microsoft. The company is well-positioned to benefit from the administration in power due to its strong U.S. manufacturing footprint, which aligns with anticipated pro-domestic policy shifts. Furthermore, valuation appears reasonable with a lower price-to-sales and price-to-free cash flow ratio relative to the broader market. Additional advantages include the release of new PC/server chips (Lunar Lake, Arrow Lake) and increasing AI involvement through Gaudi accelerators, which could provide further uplift to the struggling stock. While investing in Intel stock may carry certain risks, the Trefis Reinforced Value (RV) Portfolio has consistently outperformed its all-cap stocks benchmark (a composite of the S&P 500, S&P mid-cap, and Russell 2000 indices) to deliver robust returns for investors. What accounts for this? The quarterly rebalanced mix of large-, mid-, and small-cap RV Portfolio stocks offered an adaptable strategy to capitalize on positive market conditions while minimizing losses during downturns, as described in RV Portfolio performance metrics.
